FDA's Center for Drug Evaluation and Research (CDER) published article on its support of continuous manufacturing

In an interesting, recently published Journal of Pharmaceutical Innovation article, the FDA's CDER discusses its support of continuous manufacturing of pharmaceuticals, which has the potential to address issues of agility, flexibility, cost, and robustness in the development of pharmaceutical manufacturing processes. Additionally, the authors offer some specific insights into quality and control strategy considerations for this new manufacturing paradigm.